ERASHIGH SIGNALOPERATIONAL10-K

ERAS has significantly restructured its clinical pipeline, advancing two programs to clinical stage while discontinuing its previous lead candidate naporafenib.

The removal of all references to naporafenib as the lead product candidate and its combination development strategy represents a major strategic pivot that suggests the program may have been deprioritized or discontinued. The advancement of ERAS-0015 and ERAS-4001 to clinical stage indicates meaningful pipeline progression, but the complete elimination of the former flagship program raises questions about prior development investments and timelines.

Comparing 2026-03-12 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

ERAS shows improving operational performance with losses narrowing meaningfully across key metrics - net losses, operating losses, and cash burn all declined substantially year-over-year. However, the company's balance sheet contracted significantly with total assets declining 21% to $396M and stockholder equity falling 23% to $325M, reflecting the continued cash consumption from operations despite the improved burn rate.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-23.2%
$423.5M$325.2M

Equity decreased 23.2% — buybacks or losses reducing book value, monitor solvency ratios.

Net Income
P&L
+23%
-$161.7M-$124.5M

Net income grew 23% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+21.5%
-$179.6M-$140.9M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Assets
Balance Sheet
-21.2%
$502.5M$396.2M

Total assets contracted 21.2% — asset sales, write-downs, or balance sheet optimization underway.

Operating Cash Flow
Cash Flow
+12.8%
-$109.4M-$95.5M

Operating cash flow grew 12.8% — strong conversion of earnings to cash, healthy business fundamentals.

Total Liabilities
Balance Sheet
-10.2%
$79.0M$71.0M

Liabilities reduced 10.2% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-20
ADDED
We face significant competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms.
The trading price of the shares of our common stock has been, and is likely to continue to be highly volatile, and purchasers of our common stock could incur substantial losses.
Our focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with our three therapeutic strategies of: (1) targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; (2) targeting RAS directly; and (3) targeting escape routes that emerge in response to treatment.
Our pipeline enables us to pursue a systematic, data-driven, portfolio-wide clinical development effort to identify therapeutic approaches with the goal of prolonging survival in numerous patient populations with high unmet medical needs.
Our purpose-built pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program (an EGFR D2/D3 biparatopic antibody), for which we have identified a lead candidate.
For example, we are exploring ERAS-0015 in combination with an anti-EGFR monoclonal antibody for the treatment of patients with metastatic colorectal cancer.
To pursue these therapeutic strategies, we have assembled and are developing a pipeline targeting multiple signaling nodes to shut down the RAS/MAPK pathway.
We believe this higher binding affinity results in approximately 5 times more potent RAS inhibition in cell-based assays versus the comparator.
ERAS-0015 also has favorable absorption, distribution, metabolism and excretion (ADME) and pharmacokinetics (PK) properties in multiple animal species.
In combination with an anti-PD-1 antibody, ERAS-0015 was able to achieve complete disappearance of tumors in mice on day 31.
REMOVED
The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.
We have assembled one of the deepest RAS/MAPK pathway-focused pipelines in the industry, which comprises modality-agnostic programs aligned with our three therapeutic strategies of: (1) targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; (2) targeting RAS directly; and (3) targeting escape routes that emerge in response to treatment.
The target breadth and molecular diversity represented in our pipeline enable us to pursue a systematic, data-driven, portfolio-wide clinical development effort to identify single agent and combination approaches with the goal of prolonging survival in numerous patient populations with high unmet medical needs.
Our purpose-built pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody).
Our lead product candidate, naporafenib, targets RAF, a key node of the RAS/MAPK pathway.
We are developing naporafenib in combination with trametinib (MEKINIST) (MEK inhibitor) and other targeted therapies to delay emergence of resistance in response to RAS/MAPK pathway inhibition.
We refer to this approach as a "MAPKlamp." With this MAPKlamp approach, we hope to induce tumor regression in RAS/MAPK pathway-driven cancers, while also blocking the in-pathway escape routes that lead to tumor resistance.
To pursue these therapeutic strategies, we have assembled and are developing one of the deepest pipelines targeting multiple signaling nodes to shut down the RAS/MAPK pathway.
Our pipeline also includes ERAS-801, a brain-penetrant EGFR inhibitor in development for patients with EGFR-altered recurrent glioblastoma (GBM) (for which we are concluding a Phase 1 trial and exploring further advancement, including via partnerships and investigator-sponsored trials), ERAS-007 ERK1/2 inhibitor, and ERAS-601 SHP2 inhibitor.
ERAS-007 and ERAS-601 are being assessed in preclinical studies as potential combination partners with other programs in our pipeline for RAS/MAPK pathway inhibition.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →